Your browser doesn't support javascript.
loading
[Pulmonary complications of Chronic Granulomatous Disease]. / Complications pulmonaires de la granulomatose septique chronique.
Salvator, H; Mahlaoui, N; Suarez, F; Marcais, A; Longchampt, E; Tcherakian, C; Givel, C; Chabrol, A; Caradec, E; Lortholary, O; Lanternier, F; Goyard, C; Couderc, L J; Catherinot, E.
Afiliación
  • Salvator H; Service de pneumologie, hôpital Foch, 40, rue Worth, 92150 Suresnes, France; UMR0892 VIM-Suresnes Inrae, université Paris-Saclay, Suresnes, France; Faculté de Sciences de la Vie Simone Veil, Université Versailles Saint Quentin, Montigny-le-Bretonneux, France. Electronic address: h.salvator@hopital-f
  • Mahlaoui N; Centre de référence déficits immunitaires héréditaires (CEREDIH), hôpital Necker-Enfants Malades, institut Imagine, université Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France; Service d'hématologie-immunologie et rhumatologie pédiatrique, hôpital Necker-Enfants Malades, Assistance p
  • Suarez F; Centre de référence déficits immunitaires héréditaires (CEREDIH), hôpital Necker-Enfants Malades, institut Imagine, université Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France; Service d'hématologie adultes, hôpital Necker-Enfants Malades, université Paris Cité, Assistance publique-H
  • Marcais A; Service d'hématologie adultes, hôpital Necker-Enfants Malades, université Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France.
  • Longchampt E; Service d'anatomopathologie, hôpital Foch, Suresnes, France.
  • Tcherakian C; Service de pneumologie, hôpital Foch, 40, rue Worth, 92150 Suresnes, France.
  • Givel C; Service de pneumologie, hôpital Foch, 40, rue Worth, 92150 Suresnes, France.
  • Chabrol A; Service de pneumologie, hôpital Foch, 40, rue Worth, 92150 Suresnes, France.
  • Caradec E; Service de pneumologie, hôpital Foch, 40, rue Worth, 92150 Suresnes, France.
  • Lortholary O; Service de maladies infectieuses, hôpital Necker-Enfants Malades, Assistance publique-Hôpitaux de Paris, Paris, France; Centre national de référence des mycoses invasives et antifongiques, Centre national de la recherche scientifique, unite mixté de recherche (UMR) 2000, Institut Pasteur, université
  • Lanternier F; Service de maladies infectieuses, hôpital Necker-Enfants Malades, Assistance publique-Hôpitaux de Paris, Paris, France; Centre national de référence des mycoses invasives et antifongiques, Centre national de la recherche scientifique, unite mixté de recherche (UMR) 2000, Institut Pasteur, université
  • Goyard C; Service de pneumologie, hôpital Foch, 40, rue Worth, 92150 Suresnes, France.
  • Couderc LJ; Service de pneumologie, hôpital Foch, 40, rue Worth, 92150 Suresnes, France; UMR0892 VIM-Suresnes Inrae, université Paris-Saclay, Suresnes, France.
  • Catherinot E; Service de pneumologie, hôpital Foch, 40, rue Worth, 92150 Suresnes, France.
Rev Mal Respir ; 41(2): 156-170, 2024 Feb.
Article en Fr | MEDLINE | ID: mdl-38272769
ABSTRACT
Chronic Granulomatosis Disease (CGD) is an inherited immune deficiency due to a mutation in the genes coding for the subunits of the NADPH oxidase enzyme that affects the oxidative capacity of phagocytic cells. It is characterized by increased susceptibility to bacterial and fungal infections, particularly Aspergillus, as well as complications associated with hyperinflammation and granulomatous tissue infiltration. There exist two types of frequently encountered pulmonary manifestations (1) due to their being initially pauci-symptomatic, possibly life-threatening infectious complications are often discovered at a late stage. Though their incidence has decreased through systematic anti-bacterial and anti-fungal prophylaxis, they remain a major cause of morbidity and mortality; (2) inflammatory complications consist in persistent granulomatous mass or interstitial pneumoniae, eventually requiring immunosuppressive treatment. Pulmonary complications recurring since infancy generate parenchymal and bronchial sequelae that impact functional prognosis. Hematopoietic stem cell allograft is a curative treatment; it is arguably life-sustaining and may limit the morbidity of the disease. As a result of improved pediatric management, life expectancy has increased dramatically. That said, new challenges have appeared with regard to adults difficulties of compliance, increased inflammatory manifestations, acquired resistance to anti-infectious therapies. These different developments underscore the importance of the transition period and the need for multidisciplinary management.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad Granulomatosa Crónica Límite: Adult / Child / Humans Idioma: Fr Revista: Rev Mal Respir / Rev. mal. respir / Revue des maladies respiratoires Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad Granulomatosa Crónica Límite: Adult / Child / Humans Idioma: Fr Revista: Rev Mal Respir / Rev. mal. respir / Revue des maladies respiratoires Año: 2024 Tipo del documento: Article